6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated).

Trial Profile

6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2009 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Actual patient number (454) added as reported by ClinicalTrials.gov.
    • 16 May 2007 Status changed from 'recruiting' to 'completed'
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top